Grifols (GRFS) Stock Overview
Operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 1/6 |
| Dividends | 4/6 |
GRFS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Grifols, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €9.37 |
| 52 Week High | €11.14 |
| 52 Week Low | €6.19 |
| Beta | 1.02 |
| 1 Month Change | -5.83% |
| 3 Month Change | -12.59% |
| 1 Year Change | 6.00% |
| 3 Year Change | 42.62% |
| 5 Year Change | -49.13% |
| Change since IPO | 41.47% |
Recent News & Updates
Grifols: Significant Upside Likely Materializing
Oct 03Grifols: A Market Setback Turns Into Buying Opportunity
Apr 23Grifols: Looking At The Longer-Term 2025-2027 Upside After No Sale
Feb 27Recent updates
Shareholder Returns
| GRFS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.0% | 3.1% | 0.5% |
| 1Y | 6.0% | 3.9% | 20.1% |
Return vs Industry: GRFS exceeded the US Biotechs industry which returned 3.9% over the past year.
Return vs Market: GRFS underperformed the US Market which returned 20% over the past year.
Price Volatility
| GRFS volatility | |
|---|---|
| GRFS Average Weekly Movement | 3.3% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: GRFS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: GRFS's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1909 | 23,800 | Nacho Abia Buenache | www.grifols.com |
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factor VIII/von Willebrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease. It also markets diagnostic testing equipment, reagents, and other equipment; offers biological products and manufacturing services; and manufactures and sells plasma to third parties.
Grifols, S.A. Fundamentals Summary
| GRFS fundamental statistics | |
|---|---|
| Market cap | US$7.85b |
| Earnings (TTM) | US$342.88m |
| Revenue (TTM) | US$8.58b |
Is GRFS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GRFS income statement (TTM) | |
|---|---|
| Revenue | €7.45b |
| Cost of Revenue | €4.46b |
| Gross Profit | €2.98b |
| Other Expenses | €2.69b |
| Earnings | €297.45m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.44 |
| Gross Margin | 40.09% |
| Net Profit Margin | 3.99% |
| Debt/Equity Ratio | 112.5% |
How did GRFS perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/02 01:45 |
| End of Day Share Price | 2025/10/31 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Grifols, S.A. is covered by 32 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Guilherme Sampaio | Banco BPI, S.A. |
| null null | Banco de Sabadell. S.A. |
| Jaime Escribano | Banco Santander |